

## Endothelin Literature – Review Article

- Biology and Biochemistry
  - Pharmacology
  - Cardiovascular system
  - Renal Systems
  - Respiratory Systems
  - Cerebral vascular system
  - Reproductive system
  - ECE
  - Musculoskeletal Systems
  - Transplantation
  - GI system
  - Ophthalmology
- 

### Biology and Biochemistry

1. Inhibitors of Endothelin. ML Webb et al. *Medicinal Research Reviews*, 1997 Jan, 17(1) 17-67.
2. Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. T Godfraind et al. *Cardiovascular Drug and Therapy*, 1996 Sep, 10(4): 439-46.
3. Expression and signal transduction pathways of endothelin receptors in neuroendocrine cells. SS Stojilkovic. *Frontiers in Neuroendocrinology*, 1996 Jul, 17(3):327-69.
4. Endothelin receptors: receptor classification, novel receptor antagonists and potential therapeutic targets. EH Ohlstein et al. *Medicinal Research Reviews*, 1996 Jul, 16(4):365-90.
5. Endothelin peptides. Y Hirata. *Current Opinion in Nephrology and Hypertension*, 1996 Jan, 5(1):12-5.
6. Endothelin receptor heterogeneity, G-protein, and signaling via cAMP and cGMP cascades. M Sokolovsky. *Cellular and Molecular Neurobiology*, 1995 Oct, 15(5):561-71.
7. The development of potent peptide agonists and antagonists for the endothelin receptors. WL Code et al. *Biopolymers*, 1995 37(2):89-104.
8. Endothelin receptors and calcium signaling. DM Pollock et al. *Faseb Journal*. 1995 Sep, 9(12):1196-204.
9. Endothelins. ER Levin. *New England Journal of Medicine*, 1995 Aug 10, 333(6);356-63.
10. Endothelins: polyfunctional cytokines. MA McMillen et al. *Journal of the American College of Surgeons*. 1995 May, 180(5):621-37.
11. Endothelin receptor antagonism. TJ Opgenorth. *Advances in Pharmacology*, 1995, 33:1-65.
12. Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. M Sokolovsky. *Pharmacology and Therapeutics*, 1995, 68(3):435-71.
13. Modelling the structures of the isoforms of human endothelins based on the crystal structure of human endothelin-1. RW Janes et al. *Biochemical Society Transactions*, 1994 Nov, 22(4): 1037-43.
14. Endothelin receptor antagonists: a brief review. S Moreland. *Canadian Journal of Physiology and Pharmacology*, 1994 Nov, 72(11):1469-71.
15. Endothelin in vascular biology. T Masaki. *Ann N Y Acad Sci* 714:101-108; 1994.
16. Endothelins. Biochemistry and pathophysiologic actions. CR Gandhi et al. *Anesthesiology* 80:892-905; 1994.
17. The structure and specificity of endothelin receptors: their importance in physiology and medicine. JP Huggins et al. *Pharmacol Ther* 59:55-123; 1993.
18. Natriuretic peptides exhibit specific receptors on cultured parathyroid cells linked to endothelin synthesis and release. FML De et al. *J. Endocrinol Invest* 15(9, Suppl 6):105-111; 1992.

19. Molecular and cellular biology of endothelin and its receptors ? Part II. TF Luscher et al. *J Hypertens* 11:121-126; 1993.
20. Molecular and cellular biology of endothelin and its receptors, 1992.? Part I. TF Luscher et al. *J Hypertens* 11:7-11; 1993.
21. Cellular signaling by endothelin peptides: pathways to the nucleus. MS Simonson et al. *J Am Soc Nephrol* 2(10, Suppl):S116-S125; 1992.
22. Endothelin: a new challenge. AM Doherty. *J Med Chem* 35:1493-1508; 1992.
23. Molecular characterization of endothelin receptors. T Sakurai et al. *Trends Pharmacol Sci* 13:103-108; 1992.
24. Effects of endothelin on cultured human and rat glomerular mesangial cells. M Simonson et al. *Contrib Nephrol* 95:1-11; 1991.
25. Tissue specificity of the endothelin-induced responses. T Masaki. *J Cardiovasc Pharmacol* 17 Suppl 7:S1-S4; 1991.
26. Endothelin receptors cloned, endothelin converting enzyme characterized and pathophysiological roles for endothelin proposed. DJ Webb. *Trends Pharmacol Sci* 12:43-46; 1991.
27. Formation by the endothelium of prostacyclin, nitric oxide and endothelin. JR Vane et al. *J Lipid Mediat* 6:395-404; 1993.
28. Endothelin-induced vasoconstriction and calcium antagonists. TF Luscher et al. *J Hum Hypertens* 6 Suppl 2:S3-S8; 1992.
29. Endothelin peptides: biological activities, cellular signalling and clinical significance. J Leppaluoto et al. *Ann Med* 24:153-161; 1992.
30. Endothelin: a long-acting local constrictor hormone. WG Haynes et al. *Br J Hosp Med* 47:340-349; 1992.
31. Endothelin-1: a potent vasoactive peptide. VB Schini et al. *Pharmacol Toxicol* 69:303-309; 1991.
32. Endothelin. TF Luscher. *J Cardiovasc Pharmacol* 18 Suppl 10:S15-S22; 1991.
33. Endothelin. PE Chabrier et al. *Horm Res* 34:169-174; 1990.
34. A new vasoconstrictor peptide, endothelin: profiles as vasoconstrictor and neuropeptide. T Shigeno et al. *Cerebrovasc Brain Metab Rev* 2:227-239; 1990.
35. Cellular mechanism of vasoconstriction induced by endothelin. T Masaki et al. *Adv Second Messenger Phosphoprotein Res* 24:425-428; 1990.

---

## Pharmacology

1. Advances in clinical pharmacology and therapeutics: Endothelin. DE Newby et al. *British Journal of Hospital Medicine*, 1996 Oct 2-15, 56(7):360-4.
2. Editorial: endothelin-1, prostaglandin F<sub>2</sub> alpha, and the corpus luteum by et al. *British Journal of Hospital Medicine*, 1996 Oct 2-15, 56(7):360-4.
3. Nitric oxide and endothelin in pathophysiological settings. TE Hunley et al. *Pediatric Nephrology*, 1995 Apr, 9(2):235-44.
4. Effects and mechanisms of action of endothelins on non-vascular smooth muscle of the respiratory, gastrointestinal and urogenital tracts. GA Rae et al. *Regulatory peptides*, 1995 Jan 5, 55(1):1-46.
5. Endothelin and endothelin antagonists: pharmacology and clinical implications. TF Luscher et al. *Agents and Actions, Supplements*, 1995, 45:237-53.
6. Endothelin-releasing stimuli and calcium antagonists in normal and pathological conditions. A Morganti et al. *J Hypertens Suppl* 12: S27-S31; 1994.

7. Endothelins. A potential target for pharmacological intervention in diseases of the elderly. H Levesque et al. *Drugs Aging* 4:221-237; 1994.
8. Inhibition of the pharmacological effects of endothelin. C Wilson et al. *Prog Med Chem* 31:371-410; 1994.
9. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? AP Davenport et al. *Trends Pharmacol Sci* 15:9-11; 1994.
10. Endothelin: potential role in development and disease. V Kon et al. *Pediatr Nephrol* 7:876-880; 1993.
11. Do we need endothelin antagonists? TF Luscher. *Cardiovasc Res* 27:2089-2093; 1993.
12. Epithelioid angiosarcoma of the intestinal tract with endothelin-1-like immunoreactivity. K Watanabe et al. *Virchows Arch A Pathol Anat Histopathol* 423:309-314; 1993.
13. The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides. MS Simonson et al. *J Lab Clin Med* 119:622-639; 1992.
14. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. T Masaki et al. *Circulation* 84:1457-1468; 1991.
15. Effects of the neuroimmune mediators, peptidoleukotrienes, endothelin, and interleukin-1 on intestinal ion transport. PL Smith. *Ann N Y Acad Sci* 664:260-274; 1992.
16. Endothelin: isoforms, binding sites and possible implications in pathology. WG Nayler. *Trends Pharmacol Sci* 11:96-99; 1990.
17. The endothelin explosion. A pathophysiological reality or a biological curiosity? [comment]. BJ Whittle et al. *Circulation* 81:2022-2025; 1990

---

### Cardiovascular system

When preparing the peptide for use, please observe the following steps to maintain peptide quality:

1. Endothelium?dependent responses in congestive heart failure. PM Vanhoutte. *Journal of Molecular and Cellular Cardiology*, 1996 Nov, 28(11):2233-40.
2. The role of endothelin in the pathogenesis of atherosclerosis. MC Kowala. *Advances in Pharmacology*, 1997, 37:299-318.
3. Endothelin-1: a scientist's curiosity, or a real player in ischemic heart disease? M Cesari et al. *American Heart Journal*, 1996 Dec, 132(6):1236-43.
4. The role of endothelin in coronary atherosclerosis. V Mathew et al. *Mayo Clinic Proceedings*, 1996 Aug, 71(8):769-77.
5. A 1996 update on antihypertensive agents. JM Sullivan. *Current Opinion in Cardiology*, 1996 Sep, 11(5):496-500.
6. Is there a role for endothelin in the natural history of heart failure? JN Cohn. *Circulation*, 1996 Aug 15, 94(4):604-6.
7. Endothelin regulation of vascular tones. H Kanaide. *General Pharmacology*, 1996 Jun, 27(4):559-63.
8. Endothelin and blood pressure regulation. DJ Webb. *Journal of Human Hypertension*, 1996 Jun, 10(6):383-6.
9. Endothelin and endothelin antagonists: potential role in cardiovascular and renal diseases. G Noll et al. *Molecular and Cellular Biochemistry*, 1996 Apr 12-26, 157 (1-2):259-67.
10. Clinical potential of endothelin receptor antagonists in cardiovascular medicine. CJ Ferro et al. *Drugs*, 1996 Jan, 51(1):12-27.
11. Endothelins as cardiovascular peptides. ER Levin. *American Journal of Nephrology*, 1996, 16(3):246-51.
12. Endothelin in congestive heart failure. MP Love et al. *Basic Research in Cardiology*, 1996, 91 Suppl 1:21-9.
13. Endothelin in chronic heart failure: current position and future projects. MP Love et al. *Cardiovascular Research*, 1996 May, 31(5):665-74.

14. Role of Endothelin in the regulation of vascular tone and blood pressure. DJ Webb et al. *Contributions to Nephrology*, 1996, 119:1-7.
15. The atherogenic potential of Endothelin. D Hasdai et al. *Coronary Artery Disease*, 1995 Nov, 6(11):901-4.
16. Endothelin and endothelin receptor antagonist: roles in cardiovascular health and disease. P Tamirisa et al. *American Heart Journal*, 1995 Sep, 130 (3 pt1):601-10
17. Endothelin in hypertension. EL Schiffrin. *Current Opinion in Cardiology*, 1995 Sep, 10(5):485-94.
18. Endothelium in hypertension. EL Schiffrin. *Current Opinion in Cardiology*, 1995 Sep, 10(5):485-94. risa et al. *American Heart Journal*, 1995 Sep, 130 (3 pt1):601-10.
19. Endothelin: potential role in hypertension and vascular hypertrophy. EL Schiffrin. *Hypertension*, 1995 Jun. 25(6):1135-43.
20. Endothelin-1 and the regulation of vascular tone. M La et al. *Clinical and Experimental Pharmacology and Physiology*, 1995 May, 22(5):315-23.
21. New developments in the understanding of cerebral vasoregulation and vasospasm: the endothelinology and Physiology, 1995 May, 22(5):315-23p, 130 (3 pt1):601-10(1-2):259-67.
22. Endothelins as regulators of vascular tone in men. WG Haynes. *Clinical Science*, 1995 May, 88(5):509-17
23. Local regulation of coronary circulation in health and disease: role of nitric oxide and endothelin. TF Luscher et al. *European Heart Journal*, 1995 May, 16 Suppl C:51-8.
24. Interactions of vasoconstrictor peptides: angiotensin II and endothelin, with vasodilatory prostaglandins. H Schramek et al. *Seminars in Nephrology*, 1995 May, 15(3):195-204.
25. Possible role of endothelin in endothelial regulation of vascular tone. T Masaki. *Annual review of pharmacology and toxicology*, 1995, 35:235-55.
26. Role of intrarenal endothelin in the generation and maintenance of hypertension. BA Markewitz et al. *Mineral and Electrolyte Metabolism*, 1995, 21(4-5):342-52.
27. Endothelin and vasoactive peptides: New cardiovascular mediators. JK Gwathmey et al. *Journal of Veterinary Pharmacology and Therapeutics*, 1994 Dec, 17(6):420-5.
28. Endothelin plasma levels in hypertensive patients with vascular disease. GH Neild. *J Hypertens Suppl*, 12:S17-S20; 1994.
29. Endothelins: new players in cardiovascular physiology and disease. JL Banasik. *J Cardiovasc Nurs*, 8:87-104; 1994.
30. Structural remodeling in hypertensive heart disease and the role of hormones. KT Weber et al. *Hypertension*, 23(6, Pt 2):869-877; 1994.
31. Endothelium in the control of vascular tone and growth: role of local mediators and mechanical forces. TF Luscher. *Blood Press Suppl*, 1:18-22; 1994.
32. Endothelium and the regulation of vascular tone with emphasis on the role of nitric oxide. Physiology, pathophysiology and clinical implications. GA Rongen et al. *Neth J Med*, 44:26-35; 1994.
33. Cardiovascular protection by estrogen: a hemodynamic mechanism? S Rozenberg et al. *Int J Fertil Menopausal Stud* 39 Suppl 1:36-42; 1994.
34. Control of the circulation by vasoactive mediators from endothelial cells. JR Vane et al. *J Lipid Mediat Cell Signal* 9:1-8; 1994.
35. Platelet-vessel wall interaction: role of nitric oxide, prostaglandins and endothelins. TF Luscher. *Baillieres Clin Haematol* 6:609-627; 1993.
36. The role of endothelin in the vessel wall. PE Chabrier. *Baillieres Clin Haematol* 6:577-591; 1993.
37. Role of endothelin in hypertension. BK Kramer et al. *Clin Investig* 72:88-93; 1994.
38. Role of endothelin in heart function in health and disease. LS Golfman et al. *Can J Cardiol* 9:635-653; 1993.
39. Circulatory responses to endothelin-1 and nitric oxide with special reference to endotoxin shock and nitric oxide inhalation. E Weitzberg. *Acta Physiol Scand Suppl* 611:1-72; 1993.
40. Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. FC Tanner et al. *Semin Thromb Hemost* 19:167-175; 1993.

41. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. TF Luscher et al. *Hypertension* 21(6, Pt 1):752-757; 1993.
  42. Is endothelin involved in the pathogenesis of hypertension? PM Vanhoutte. *Hypertension* 21(6, Pt 1):747-751; 1993.
  43. The potential role of endothelin as a vasoconstrictor substance in congestive heart failure. RJ Cody. *Eur Heart J* 13:1573-1578; 1992.
  44. Endothelin and calcium dynamics in vascular smooth muscle. RF Highsmith et al. *Annu Rev Physiol* 54:257-277; 1992.
  45. Cardiovascular effects of endothelin. K Goto et al. *Jpn Circ J* 56:162-169; 1992.
  46. Role of EDRF and endothelin in coronary vasomotor control. DJ Stewart. *Basic Res Cardiol* 86 Suppl 2:77-87; 1991.
  47. Role of endothelin in mechanisms of local blood pressure control. T Masaki et al. *J Hypertens Suppl* 8:S107-S112; 1990.
  48. Endothelin: a new cardiovascular regulatory peptide. A Lerman et al. *Mayo Clin Proc* 65:1441-1455; 1990.
  49. Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. M. Yanagisawa et al. *Biochem Pharmacol* 38:1877-1883; 1989.
  50. Does endothelin-1 mediate endothelium-dependent contractions during anoxia? PM Vanhoutte et al. *J Cardiovasc Pharmacol* 13 Suppl 5:S124-S128; 1989. discussion S142.
- 

## Renal Systems

1. Endothelin in renal pathophysiology: from experimental to therapeutic application. TJ Rabelink et al. *Kidney International*, 1996 Dec, 50(6):1827-33.
2. Endothelin antagonists on the clinical horizon in nephrology. TJ Rabelink et al. *Current Opinion in Nephrology and Hypertension*. 1996 Sept, 5(5): 389-92.
3. Endothelins in the normal and diseased kidney. DE Kohan. *American Journal of Kidney Diseases*. 1997 Jan, 29(1):2-26.
4. Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and an endothelin receptor antagonist on renal afferent arteriolar structure. K Skov et al. *Hypertension*, 1996 sep, 28(3):464-71.
5. Endothelin: What role in acute contrast nephropathy? P Gross et al. *Nephrology, Dialysis, Transplantation*, 1996 Sep, 11(9):1716-8.
6. Perspectives in endothelin research: tubulointestinal actions of endothelins in the kidney: roles in health and disease. AC Ong. *Nephrology, Dialysis, Transplantation*, 1996 Feb, 11(2):251-7.
7. Endothelin and endothelin antagonists: potential role in cardiovascular and renal diseases. G Noll et al. *Molecular and Cellular Biochemistry*, 1996 Apr 12-26, 157 (1-2):259-67.
8. Endothelin receptors in normal and diseased kidneys. P Nambi. *Clinical and Experimental Pharmacology and Physiology*, 1996 Apr 23(4):236-30.
9. Signaling pathways activated by endothelin stimulation of renal cells. EP Nord. *Clinical and Experimental Pharmacology and Physiology*, 1996 Apr 23(4):331-6.
10. Endothelin: renal tubule synthesis and actions. ED Kohan. *Clinical and Experimental Pharmacology and Physiology*, 1996 Apr, 23(4):337-44.
11. Role of Endothelin in the development of glomerulosclerosis. G Remuzzi. *Kidney and Blood Pressure Research*, 1996, 19(3-4):182-3.
12. Endothelin in diabetic kidneys. H Koide et al. *Kidney International. Suppl*, 1995 Sep. 51:S45-9.

13. Refining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. A Benigni. *Current Opinion in Nephrology and Hypertension*, 1995 Jul, 4(4):349-53.
14. Endothelin in the progressive renal disease of glomerulopathies. A Benigni et al. *Mineral and Electrolyte Metabolism*, 1995, 21(4-5):283-91.
15. Role of intrarenal endothelin in the generation and maintenance of hypertension. BA Markewitz et al. *Mineral and Electrolyte Metabolism*, 1995, 21(4-5):342-52.
16. Endothelin in renal disease: role of endothelin antagonists (editorial). TF Luscher et al. *Nephrology, Dialysis, Transplantation*, 1995, 10(2):162-5.
17. Endothelin in chronic renal failure [editorial]. K Takahashi et al. *Nephron* 66:373-379; 1994.
18. Renal adaptation to the failing heart. Understanding the cascade of responses. DJ Riley et al. *Postgrad Med* 95:141-6,149-50; 1994.
19. Renal function in patients receiving long-term cyclosporine therapy. BDH Van et al. *J Am Soc Nephrol* 4(8, Suppl):S17-S22; 1994.
20. Renal actions of endothelin: linking cellular signaling pathways to kidney disease. TA Marsen et al. *Kidney Int* 45:336-344; 1994.
21. Urinary endothelin: a possible biological marker of renal damage. ZA Abassi et al. *Am J Hypertens* 6:1046-1054; 1993.
22. Biological actions and pathophysiologic significance of endothelin in the kidney [editorial]. V Kon et al. *Kidney Int* 40:1-12; 1991.
23. Role of endothelin in glomerular injury. N Perico et al. *Kidney Int Suppl* 39:S76-S80; 1993.
24. Endothelin peptides and the kidney. MS Simonson et al. *Annu Rev Physiol* 55:249-265; 1993.
25. The possible role of endothelin in the process of progressive renal deterioration in experimental and human glomerulopathies. N Perico et al. *Semin Nephrol* 13:137-143; 1993.
26. Vascular endothelin and renal disease progression. N Perico et al. *Contrib Nephrol* 100:236-253; 1992.
27. An emerging role for endothelin in renal disease [editorial; comment]. PJ Shultz. *J Lab Clin Med* 119:448-449; 1992.
28. Cytosolic and nuclear signaling by endothelin peptides: mesangial response to glomerular injury. MS Simonson et al. *Kidney Int* 41:542- 545; 1992.
29. Regulation of NaCl transport by endothelin in renal tubules. K Tomita et al. *Semin Nephrol* 12:30-36; 1992.
30. Endothelin: an important factor in acute renal failure? JD Firth et al. *Lancet* 2:1179-1182; 1988.
31. Effects and mechanisms of action of endothelins on non-vascular smooth muscle of the respiratory, gastrointestinal and urogenital tracts. GA Rae et al. *Regulatory peptides*, 1995 Jan 5, 55(1):1-46.

---

## Respiratory Systems

1. Phosphodiesterase inhibitors and endothelin as modulators of respiratory neurotransmission. LB Fernandes. *Clinical and Experimental Pharmacology and Physiology*, 1996 Oct-Nov, 23(10-11): 980-2.
2. Endothelin as inhibitors and endothelin as modulators of respiratory neurotransmission. LB Fernandes. *Clinical and Experimental Pharmacology*
3. Endothelins and lung. JR Michael et al. *American Journal of Respiratory and Critical Care Medicine.*, 1996 Sep, 154 (3 pt1): 555-81.
4. Epithelially derived endothelin and nitric oxide in asthma. PH Howarth et al. *International Archives of Allergy and Immunology*, 1995 May-Jun, 107(1-3):228-30.

5. Endothelin in cardiopulmonary disease: factor paracrine vs neurohumoral. DJ Stewart. *Eur Heart J* 14 Suppl I:48-54; 1993.
6. Endothelin: systemic arterial and pulmonary effects of a new peptide with potent biologic properties. TF Luscher. *Am Rev Respir Dis* 146 (5, Pt 2):S56-S60; 1992.
7. Endothelin peptides: biological actions and pathophysiological significance in the lung. JG Filep. *Life Sci* 52:119-133; 1993.
8. Endothelin and the respiratory system. DW Hay et al. *Trends Pharmacol Sci* 14:29-32; 1993.
9. Role of endothelin in pulmonary function. F Pons et al. *Pulm Pharmacol* 5:213-219; 1992.
10. Bronchopulmonary effects of endothelin. V Lagente et al. *Clin Exp Allergy* 20:343-348; 1990.

---

### Cerebral vascular system

1. Endothelin peptide in brain diseases. XJ Nie et al. *Reviews in the Neurosciences*, 1996 July-Sep, 7(3):177-86.
2. Therapeutic effects of endothelin receptors antagonists in stroke. FC Barone et al. *Neurological Research*, 1995 Aug, 17(4): 259-64/
3. Endothelins and cerebral circulation. JB Salom et al. *Cerebrovascular and Brain Metabolism Review*. 1995 Summer, 7(2):131-52/
4. New developments in the understanding of cerebral vasoregulation and vasospasm: the endothelin/nitric oxide network. H Ehrenreich et al. *Cleveland Clinic Journal of Medicine*, 1995 Mar-Apr, 62(2):105-16.
5. Endothelin, cerebral ischaemia and infarction. JL Reid et al. *Clinical and experimental hypertension*, 1995 Jan-Feb, 17(1-2):399-407.
6. Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm? F Cosentino et al. *Stroke* 25:904-908; 1994.
7. The effect of endothelin-1 on the cerebrovascular response to hypoxia and hypercapnia in the newborn. JV Aranda et al. *Semin Perinatol* 16:196-199; 1992.
8. Cerebrospinal fluid endothelin-1 and endothelin-3 levels in normal and neurosurgical patients: a clinical study and literature review. GE Kraus et al. *Surg Neurol* 35:20-29; 1991.

---

### Reproductive system

1. Effects of endothelin-1 and the ETA receptor antagonist BQ-123 on resistance arteries from normal pregnant and preeclamptic women. K Wolff et al. *Acta Obstetrica et Gynecologica Scandinavica*. 1996 May, 75(5):432-8.
2. Preeclampsia and related disorders. Clinical aspects and relevance of endothelin and nitric oxide. SA Friedman et al. *Clinics in Perinatology*, 1995 Jun 22(2):343-55.
3. Inositol lipid-mediated signaling in response to endothelin and ATP in the mammalian testis. SA Rudge. *Molecular and Cellular Biochemistry*, 1995 Aug-Sep, 149-150:161-74.
4. Vasoactive peptides and uterine vessels. M Stjernquist et al. *Gynecological Endocrinology*, 1995 Jun, 9(2):165-76.
5. Endothelin and the placenta. S Handwerker. *Journal of Laboratory and Clinical Medicine*, 1995 Jun 125(6):679-81.

6. Endothelin - its possible role during pregnancy. F Ferre. *European Journal of Obstetric, Gynecology and Reproductive Biology*. 1995 Mar, 59(1):1-4.
  7. Effects and mechanisms of action of endothelins on non-vascular smooth muscle of the respiratory, gastrointestinal and urogenital tracts. GA Rae et al. *Regulatory peptides*, 1995 Jan 5, 55(1):1-46.
  8. Endothelin receptors and gonadal function: an invited commentary. SS Stojilkovic. *European Journal of Endocrinology*, 1996 Oct, 135(4):391-3.
  9. Oxytocin-endothelin interactions in the uterus. M Maggi et al. *Regul Pept* 45:97-101; 1993.
  10. Endothelin in perinatal pharmacology. T Masaki et al. *Semin Perinatol* 15:27-29; 1991.
- 

### ECE

1. 1. Molecular Pharmacology of endothelin converting enzymes. AJ Turner et al. *Biochemical Pharmacology*, 1996 Jan 26, 51(2):91-102.
  2. Endothelin-converting enzymes and other families of metallo-endopeptidases. AJ Turner. *Biochem Soc Trans* 21:(Pt3)(3) 697-701, 1993.
  3. Endothelin-converting enzymes. TJ Opgenorth et al. *Faseb J* 6:2653-2659; 1992.
- 

### Musculoskeletal Systems

1. Endothelin receptors, second messengers, and actions in bone. PH Stern et al. *Journal of Nutrition*, 1995 Jul, 125(7 Suppl):2028S-2032S.
- 

### Transplantation

1. Endothelin in organ transplantation. B Watschinger. *American Journal of Kidney Diseases*, 1996 Jan, 27(1):151-61.
- 

### GI system

1. Multiple hepatic functions of endothelin-1: physiopathological relevance. A Mallat et al. *Journal of Hepatology*. 1996 Sep, 25(3):405-13.
  2. Hepatic lipocytes: a major target for endothelin-1. CN Housset. *Journal of Hepatology*, 1995, 22(2 Suppl):55-60.
- 

### Ophthalmology

1. Endothelin: a new vasoactive ocular peptide. U Chakravarthy et al. *Br J Ophthalmol* 76:107-108; 1992.

## American Peptide Company, Inc

### **Headquarters**

777 East Evelyn Ave.  
Sunnyvale, CA 94086  
USA

Phone: (408)733-7604

Fax: (408)733-7603

### **cGMP Manufacturing**

1271 Avenida Chelsea  
Vista, CA 92081  
USA

Phone: (760) 597-8820

Fax: (760) 597-8816

Toll free phone: (800) 926-8272 fax: (888) 670-0070

Email: [sales@americanpeptide.com](mailto:sales@americanpeptide.com),

URL: [www.americanpeptide.com](http://www.americanpeptide.com)